STOCK TITAN
  1. Home
  2. News
  3. CLLS

Cellectis - CLLS STOCK NEWS

Welcome to our dedicated news page for Cellectis (Ticker: CLLS), a resource for investors and traders seeking the latest updates and insights on Cellectis.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Cellectis's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Cellectis's position in the market.

News
Cellectis Publishes a Novel Intronic Gene Editing Approach For the Treatment of Inborn Metabolic Diseases by Edited HSPCs
Rhea-AI Summary
Cellectis (NASDAQ: CLLS) announces a breakthrough in gene-editing therapy with the publication of a new research paper. The study demonstrates the potential of TALEN-mediated intron editing in HSPCs for targeted transgene expression, offering new treatment possibilities for metabolic and neurological diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.36%
Tags
none
-
News
Cellectis Announces Two Poster Presentations on Novel TALEN® Editing Process for Gene Correction and Gene Insertion in HSPCs at the ASGCT Annual Meeting
Rhea-AI Summary
Cellectis, a biotechnology company, announced the presentation of preliminary data on a novel TALEN® gene-editing process for hematopoietic stem cells at the ASGCT 27th Annual Meeting. The company showcased improvements in gene correction and insertion in HSPCs, along with a strategy for lineage-specific expression of therapeutics.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.23%
Tags
none
-
News
Monthly information on share capital and company voting rights
Rhea-AI Summary
Cellectis announces voting rights for March 2024 with a total of 77,889,229 voting rights from 71,953,535 shares in the capital, listed on Euronext Growth with ISIN code FR0010425595.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.55%
Tags
none
News
Monthly information on share capital and company voting rights
Rhea-AI Summary
Cellectis announces voting rights for February 2024 with a total of 77,686,895 voting rights and 71,751,201 shares in the capital. The company's ISIN code is FR0010425595, listed on Euronext Growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.62%
Tags
none
-
News
Monthly information on share capital and company voting rights
Rhea-AI Summary
Cellectis (CLLS) reports a total number of shares in the capital and voting rights as of January 31, 2024. The company's ISIN code is FR0010425595 and is listed on Euronext Growth. Media and investor relations contacts are provided for further information.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Cellectis announces the drawdown of the second tranche of €15 million under the credit facility agreement entered with the European Investment Bank (EIB)
Rhea-AI Summary
Cellectis, a clinical-stage biotechnology company, has announced the drawdown of the second tranche of €15 million under a credit facility agreement with the European Investment Bank. The company plans to use the proceeds towards the development of its pipeline of allogeneic CAR T-cell product candidates. As a condition to the disbursement, the company issued warrants to the EIB, allowing them to subscribe for one ordinary share of the company at a specific price. The total number of shares issuable upon exercise of the warrants represents circa 2% of the company’s outstanding share capital at their issuance date. The tranche will mature in six years and accrue interest at a rate of 7% per annum. The company also has the option to drawdown a third tranche of up to €5 million, subject to certain conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.42%
Tags
none
News
Monthly information on share capital and company voting rights
Rhea-AI Summary
Cellectis (Euronext Growth: FR0010425595) reports a total number of shares in the capital as 71,751,201 and a total number of voting rights as 77,686,718 as of December 31, 2023. For further information, media contact is Patricia Sosa Navarro at +33 (0)7 76 77 46 93, media@cellectis.com. Investor Relations contacts are Arthur Stril at +1 (347) 809 5980, investors@cellectis.com and Ashley R. Robinson at +1 617 430 7577.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.33%
Tags
none
-
News
Cellectis Reports Results from Shareholders Meeting Held on December 22, 2023
Rhea-AI Summary
Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS) held a shareholders general meeting at which resolutions 1 through 5 and 7 and 8 were adopted and resolution 6 was rejected. Shareholders supported a contemplated $140M additional investment by AstraZeneca, subject to clearance from the French Ministry of Economy. Mr. Marc Dunoyer and Dr. Tyrell Rivers were approved as directors of the Cellectis board of directors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Monthly information on share capital and company voting rights
Rhea-AI Summary
Cellectis (Euronext Growth: ALCLS) reports a total number of 71,751,201 shares in the capital and 77,686,109 voting rights as of November 30, 2023. For further information, please contact Media Chief of Staff Patricia Sosa Navarro at +33 (0)7 76 77 46 93 or media@cellectis.com, and Investor Relations Chief Business Officer Arthur Stril at +1 (347) 809 5980 or investors@cellectis.com.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News
Cellectis’ Shareholders Meeting to be Held on December 22, 2023
Rhea-AI Summary
Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS) to hold a general meeting on December 22, 2023, at 2:30 p.m. CET at the Biopark auditorium in Paris, France. The notice of meeting, agenda, resolutions, and terms of participation are available on the Cellectis website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Stock CLLS logo
Cellectis

Nasdaq:CLLS

CLLS Rankings

#3821 Ranked by Market Cap
#4900 Ranked by Stock Gains
N/A Ranked by Dividends

CLLS Stock Data

203.24M
33.22M
12.13%
18.83%
0.94%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
France
Paris

About CLLS

cellectis is a clinical-stage biopharmaceutical company focused on developing a new generation of cancer immunotherapies based on gene-edited t-cells (ucart). by capitalizing on its 18 years of expertise in gene editing – built on its flagship talen® technology and pioneering electroporation system pulseagile – cellectis uses the power of the immune system to target and eradicate cancer cells. using its life-science-focused, pioneering genome engineering technologies, cellectis’ goal is to create innovative products in multiple fields and with various target markets. cellectis is listed on the nasdaq market (ticker: clls) and on the nyse alternext market (ticker: alcls). to find out more about us, visit our website: www.cellectis.com talking about gene editing? we do it. talen® is a registered trademark owned by the cellectis group.